Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. - sprookjes - yvandenbroek - TriplyDB

Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins.

Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins.

http://www.wikidata.org/entity/Q34127850

about

Metabolism of vertebrate amino sugars with N-glycolyl groups: elucidating the intracellular fate of the non-human sialic acid N-glycolylneuraminic acid Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes Fc glycans of therapeutic antibodies as critical quality attributes Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics In vitro and in vivo modifications of recombinant and human IgG antibodies Protein comparability assessments and potential applicability of high throughput biophysical methods and data visualization tools to compare physical stability profiles Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium Optimization of pre-transplantation conditions to enhance the efficacy of mesenchymal stem cells Glycan analysis of therapeutic glycoproteins Measurement of cetuximab and panitumumab-unbound serum EGFR extracellular domain using an assay based on slow off-rate modified aptamer (SOMAmer) reagents Current Status: Site-Specific Antibody Drug Conjugates Human risk of diseases associated with red meat intake: Analysis of current theories and proposed role for metabolic incorporation of a non-human sialic acid Capillary electrophoresis-mass spectrometry of carbohydrates.Immunogenicity of panitumumab in combination chemotherapy clinical trials Sialic acid speciation using capillary electrophoresis: optimization of analyte derivatization and separation.A red meat-derived glycan promotes inflammation and cancer progression A simple method for assessment of human anti-Neu5Gc antibodies applied to Kawasaki disease Exploration of sialic acid diversity and biology using sialoglycan microarrays.Characterization of N-Linked Glycosylation in a Monoclonal Antibody Produced in NS0 Cells Using Capillary Electrophoresis with Laser-Induced Fluorescence Detection Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development Glycosylation profiles determine extravasation and disease-targeting properties of armed antibodies The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line Site-specific qualitative and quantitative analysis of the N- and O-glycoforms in recombinant human erythropoietin.Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function.Limited Addition of the 6-Arm β1,2-linked N-Acetylglucosamine (GlcNAc) Residue Facilitates the Formation of the Largest N-Glycan in Plants Rapid Screening of Bovine Milk Oligosaccharides in a Whey Permeate Product and Domestic Animal Milks by Accurate Mass Database and Tandem Mass Spectral Library.Nutrient-deprived cancer cells preferentially use sialic acid to maintain cell surface glycosylation.Innovative use of a bacterial enzyme involved in sialic acid degradation to initiate sialic acid biosynthesis in glycoengineered insect cells.Sialic acid metabolism and sialyltransferases: natural functions and applications.At least two Fc Neu5Gc residues of monoclonal antibodies are required for binding to anti-Neu5Gc antibody Pre-existing Antibody: Biotherapeutic Modality-Based Review.In-depth characterization of N-linked oligosaccharides using fluoride-mediated negative ion microfluidic chip LC-MS Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars.The GlycoFilter: a simple and comprehensive sample preparation platform for proteomics, N-glycomics and glycosylation site assignment Preferential lectin binding of cancer cells upon sialic acid treatment under nutrient deprivation A method for high-throughput, sensitive analysis of IgG Fc and Fab glycosylation by capillary electrophoresis Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives.Involvement of a non-human sialic Acid in human cancer.Fabry disease, enzyme replacement therapy and the significance of antibody responses.

P2860

Q24338142-BAFD858F-12B0-44B8-8BD0-012E4559C910 Q26738810-D65E3E6E-527D-46AE-A00E-57A0FB4A7D3A Q26766424-E3901D2D-E652-4858-96B8-CB4FB6DD8D9E Q26799266-75F43AE8-12C0-4FE4-8BAD-1FAE4029BB41 Q26822421-3B331B3C-E147-4098-A4FA-B2AF36603435 Q26859713-22AC0444-6B9D-4B9E-B0BD-B78C6D3CF038 Q26998787-A88F22E9-D0A7-4B9F-A015-B23C3AF867B5 Q27009385-B60EE610-287E-4A8B-9862-CF683811980A Q27015774-68657EEF-8597-4F4C-84AC-CDB3BED7F9EA Q28082842-F6C01754-CC5A-4A6F-A6DF-0AD690BB3CF8 Q28535487-6F58E665-04D3-4501-8055-D98304227445 Q28829290-8F56BE9B-788B-4EBA-BC59-71A73063862C Q30248988-FAF3AD4A-D1D9-468D-A00E-A02D70753F42 Q33939419-99CD3231-2BC4-48FE-A8A3-D90211BD153B Q34070944-FBA6B9C7-041B-4CF0-BEE4-F3A0150EECD6 Q34383299-9CA9595B-754E-4D26-97A8-6F30FBE8B8E6 Q34455992-96DB61B0-350F-4E1A-A5CF-C686E1F6C0BE Q34631810-A3851957-18A6-4CFB-AD7A-83364347F73D Q34772126-4E56ACC8-E22A-4C18-9FCA-F5D30A2AA2D1 Q35052763-068FE762-82E5-4038-B508-78D0F71BDAC9 Q35105725-883E9FBA-DA29-4A40-B363-48EDD14C49EF Q35129041-57EB6A89-C58F-4794-99A5-475AC6CD88C1 Q35188192-7A0BBCED-E73D-4D0A-BFD8-69FB7EB9EB96 Q35577821-1B2667B8-1A16-4397-A5C8-D4F8DB9B84E5 Q35600028-5C9B4974-7AB2-4C39-9B01-2FE08112212A Q35860484-C0DB1BFA-B8F9-40EC-A7C3-1D66E034CF46 Q36080170-A1B4DEC5-60C8-4AD5-ACCB-B2CD7E0A2CB9 Q36315969-49D4A73E-7702-4352-AFC3-726EDA18958D Q36392872-0496A73D-D97B-4480-908C-259948766171 Q36501918-60EB625D-0970-421D-BD7F-CDC32915C195 Q36517187-4A1D0C00-6446-487A-88F5-3C4617B12F88 Q36653888-CD0EFA62-ACA4-40FA-9AAF-D2074CA4BE7A Q36704033-F6346185-509B-4785-BA3E-B1FDFA407B29 Q37022207-7EB09D1A-5DDC-45A7-B53E-F72B17F99588 Q37214717-CAFC442C-593A-4E6B-B906-8452E896BAF0 Q37269017-DD6621A3-83C0-46B3-930F-20C897851371 Q37319976-33FE4B77-292E-458B-AF75-D8835DE5FE35 Q37494846-96A5601A-B18F-4BE6-9EB1-0FA5C660454C Q37592596-34610FFD-1D9A-4EBB-82FF-30B32AE4EDE2 Q37950838-B0C5EA2B-5385-4906-818E-B2E3085CDF82

P2860

Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins.

http://www.wikidata.org/entity/Q34127850

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Implications of the presence o ...... ant therapeutic glycoproteins.

@ast

Implications of the presence o ...... ant therapeutic glycoproteins.

@en

Implications of the presence o ...... ant therapeutic glycoproteins.

@nl

type

label

Implications of the presence o ...... ant therapeutic glycoproteins.

@ast

Implications of the presence o ...... ant therapeutic glycoproteins.

@en

Implications of the presence o ...... ant therapeutic glycoproteins.

@nl

prefLabel

Implications of the presence o ...... ant therapeutic glycoproteins.

@ast

Implications of the presence o ...... ant therapeutic glycoproteins.

@en

Implications of the presence o ...... ant therapeutic glycoproteins.

@nl

P1433

Q34127850-8790377F-8958-47E6-AD5D-850E0BC880F4

P1476

Q34127850-381AD898-8A06-4F4D-BEF9-499843F615DD

P2093

Q34127850-829B06B0-E595-4854-B534-02AED20F4FC8

Q34127850-A1F11E13-9F59-44E2-91AE-F6CC3A813A30

Q34127850-D4B27E10-85DF-428E-A8B0-8648F1E42841

Q34127850-D7ECA87F-A348-4A37-A559-C9C3EC3CA106

Q34127850-F8C2B7E7-862F-4947-8500-7272CBB67C5F

P2860

Q34127850-10DF879E-0351-49F0-8691-1DDD43BF02AE

Q34127850-13C88317-922E-4E56-8109-8D3372E6AD1F

Q34127850-1FD9F7E0-8A88-4147-A42B-DEC01E0A1F80

Q34127850-2189D9AE-7167-4EED-8D4F-E8E3FE7D2C4C

Q34127850-263285F7-6E14-45C2-B7CB-73FE499ED090

Q34127850-26B33445-E4B0-4657-AA52-DF034E2A2AD3

Q34127850-2B4F93BE-F1CD-459C-9268-80F16434AB17

Q34127850-2DA068EC-BA8C-4B65-BC4D-C8547A3BDEF7

Q34127850-3E719609-7D91-44A0-B63E-4B2A82082550

Q34127850-4CEA3E13-34ED-43D5-84A3-4BD453BD5BC2

P2888

Q34127850-937B9ACC-A288-4259-8CD8-39CB0E40163F

P304

Q34127850-D6FB3C6D-D8EB-4EEA-ADD9-21F9EE049457

P31

Q34127850-8213D0A1-3642-417C-B40E-425BEAADB5E9

P356

Q34127850-D1C86CB6-49BD-4AFD-A0B6-6B9C37D1DCE8

P433

Q34127850-B7F907AD-CF1B-4DAD-9A8A-5163F0F31BC4

P478

Q34127850-A1C59558-7F5B-4477-8DC5-1808F42CCD80

P577

Q34127850-BF9BDEEA-E905-4F78-8249-8F6A62ECD8A8

P5875

Q34127850-E4713066-01B7-4439-9499-C0D2423B69BC

P6179

Q34127850-B844A504-DB91-4EDF-BC61-177C1D7E44F3

P698

Q34127850-3E82A8A7-D368-497A-9703-3556D9509594

P932

Q34127850-BA84B867-2B38-4901-9DC7-023083DF958E

P356

P1433

Nature Biotechnology

P1476

Implications of the presence o ...... ant therapeutic glycoproteins.

@en

P2093

Ajit Varki

http://www.w3.org/2001/XMLSchema#string

Darius Ghaderi

http://www.w3.org/2001/XMLSchema#string

Rachel E Taylor

http://www.w3.org/2001/XMLSchema#string

Sandra Diaz

http://www.w3.org/2001/XMLSchema#string

Vered Padler-Karavani

http://www.w3.org/2001/XMLSchema#string

P2860

Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

N-glycolylneuraminic acid deficiency in mice: implications for human biology and evolution

Nontypeable Haemophilus influenzae strain 2019 produces a biofilm containing N-acetylneuraminic acid that may mimic sialylated O-linked glycans

Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequentia

Sensitive and specific detection of the non-human sialic Acid N-glycolylneuraminic acid in human tissues and biotherapeutic products

Novel mechanism for the generation of human xeno-autoantibodies against the nonhuman sialic acid N-glycolylneuraminic acid.

Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells.

Human embryonic stem cells express an immunogenic nonhuman sialic acid.

Glycan-based interactions involving vertebrate sialic-acid-recognizing proteins.

P2888

P304

863-867

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NBT.1651

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45288468

http://www.w3.org/2001/XMLSchema#string

P6179

1029307185

http://www.w3.org/2001/XMLSchema#string

P698

20657583

http://www.w3.org/2001/XMLSchema#string

P932

3077421

http://www.w3.org/2001/XMLSchema#string